Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production
In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape. The post Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production appeared first on GEN - Genetic Engineering and Biotechnology News .
In the biomanufacturing sector, there are intricate requirements surrounding fermentation scale-up, process consistency, technology transfer, and manufacturing capacity that must be tackled for microbial-derived biologics to attain commercialization. These challenges necessitate specialized infrastructure and an integrated approach for process validation, process performance qualification (PPQ), and long-term operational readiness.
During a GEN webinar scheduled for Tuesday, September 29, 2026, at 08:00 PDT, 11:00 EDT, and 17:00 CET, Sam Zhang, PhD, Vice President and Head of Microbial and Viral Platforms at WuXi Biologics, will delve into emerging trends and capacity requirements in the global late-stage microbial pipeline and contract development and manufacturing organization (CDMO) landscape.
Zhang will showcase WuXi Biologics' comprehensive late-stage microbial capabilities, including their recently built commercial facility in Chengdu, China, tailored for microbial-derived biologics.
Zhang will also demonstrate the platform's features for comprehensive tech transfer and scale-up, as well as PPQ and commercial readiness strategies. A case study focusing on a peptide program will be highlighted, illustrating WuXi Biologics' customized solutions for microbial-derived biologics. Key takeaways from the event include critical success factors for technology transfer, large-scale microbial manufacturing at the Chengdu site (capable of fermentation up to 15,000 L), and practical insights from a complex peptide program applicable to recombinant proteins and other microbial-derived modalities.
A live Q&A session will follow the presentations, providing attendees with an opportunity to submit questions to Zhang and other expert panelists. This webinar, supported by GEN, offers invaluable information for professionals in the biopharmaceutical industry navigating the complexities of microbial-derived biologics' scale-up to commercial production.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
